Camilla Fröhlich

Title: Camilla Fröhlich: Innovator in Combination Therapies

Introduction

Camilla Fröhlich is a prominent inventor based in København Ø, Denmark. She has made significant contributions to the field of immunotherapy, particularly in the development of combination therapies targeting critical immune checkpoints. With a total of 5 patents, her work is paving the way for innovative treatments in oncology.

Latest Patents

Fröhlich's latest patents include groundbreaking inventions such as "Combination therapies targeting PD-1, TIM-3, and LAG-3." This disclosure relates to therapies that utilize antibodies specific for these targets, aimed at enhancing immunity in patients suffering from various diseases, including cancers. Another notable patent is for "Anti-LAG-3 antibodies and compositions," which focuses on methods of using these antibodies to treat conditions that benefit from modulating LAG-3 activity, particularly in cancer treatment.

Career Highlights

Throughout her career, Fröhlich has worked with esteemed organizations, including Les Laboratoires Servier and Symphogen A/S. Her expertise in immunotherapy has positioned her as a key figure in the development of novel therapeutic strategies.

Collaborations

Fröhlich has collaborated with notable professionals in her field, including Michael Monrad Grandal and Torben Gjetting. These partnerships have further enhanced her research and development efforts.

Conclusion

Camilla Fröhlich's innovative work in combination therapies and her commitment to advancing cancer treatment exemplify her significant role in the field of immunotherapy. Her contributions continue to inspire future research and development in this critical area of medicine.